{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Squamous+Cell+Carcinoma%2C+Not+Otherwise+Specified&page=52", "query": { "condition": "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "page": 52 }, "page_size": 10 }, "pagination": { "page": 52, "page_size": 10, "total_count": 1559, "total_pages": 156, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Squamous+Cell+Carcinoma%2C+Not+Otherwise+Specified&page=53&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Squamous+Cell+Carcinoma%2C+Not+Otherwise+Specified&page=51&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T19:26:24.635Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03665285", "title": "A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Lung Cancer", "Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Endometrial Cancer", "Melanoma", "CRC", "Urothelial Carcinoma", "Cholangiocarcinoma" ], "interventions": [ { "name": "NC318", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NextCure, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "2018-10-01", "completion_date": "2023-04-11", "has_results": true, "last_update_posted_date": "2024-03-08", "last_synced_at": "2026-10-25T19:26:24.635Z", "location_count": 6, "location_summary": "Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Gettysburg", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03665285" }, { "nct_id": "NCT00216138", "title": "Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Premedication", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoosier Cancer Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2004-03", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2011-05-02", "last_synced_at": "2026-10-25T19:26:24.635Z", "location_count": 18, "location_summary": "Newark, Delaware • Chicago, Illinois • Elkhart, Indiana + 13 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Elkhart", "state": "Indiana" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00216138" }, { "nct_id": "NCT03944915", "title": "De-Escalation Therapy for Human Papillomavirus Negative Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Papilloma Virus", "Squamous Cell Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "HPV-Related Squamous Cell Carcinoma", "HNSCC" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Hydroxyurea Pill", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Filgrastim Injection", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2019-08-26", "completion_date": "2023-11-01", "has_results": true, "last_update_posted_date": "2025-05-11", "last_synced_at": "2026-10-25T19:26:24.635Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03944915" }, { "nct_id": "NCT00017004", "title": "Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Squamous Cell Carcinoma", "Drug Toxicity", "Radiation Toxicity", "Stage IIB Cervical Cancer", "Stage III Cervical Cancer", "Stage IVA Cervical Cancer" ], "interventions": [ { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Internal Radiation Therapy", "type": "RADIATION" }, { "name": "Epoetin Alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "DRUG", "BIOLOGICAL" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 114, "start_date": "2001-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-08-09", "last_synced_at": "2026-10-25T19:26:24.635Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00017004" }, { "nct_id": "NCT04458909", "title": "Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Nasopharyngeal Carcinoma", "Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Metastatic Nasopharyngeal Nonkeratinizing Carcinoma", "Metastatic Nasopharyngeal Undifferentiated Carcinoma", "Nasopharyngeal Nonkeratinizing Carcinoma", "Recurrent Nasopharyngeal Carcinoma", "Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Recurrent Nasopharyngeal Undifferentiated Carcinoma", "Stage IV Nasopharyngeal Carcinoma AJCC v8", "Stage IVA Nasopharyngeal Carcinoma AJCC v8", "Stage IVB Nasopharyngeal Carcinoma AJCC v8" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2020-12-09", "completion_date": "2023-08-15", "has_results": true, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-10-25T19:26:24.635Z", "location_count": 322, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 204 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04458909" }, { "nct_id": "NCT03277352", "title": "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies", "Metastatic Cancer" ], "interventions": [ { "name": "INCAGN01876", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2017-11-21", "completion_date": "2020-07-01", "has_results": true, "last_update_posted_date": "2021-07-22", "last_synced_at": "2026-10-25T19:26:24.635Z", "location_count": 2, "location_summary": "Los Angeles, California • Hackensack, New Jersey", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03277352" }, { "nct_id": "NCT02466971", "title": "Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Vaginal Adenocarcinoma", "Advanced Vaginal Adenosquamous Carcinoma", "Advanced Vaginal Squamous Cell Carcinoma", "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Squamous Cell Carcinoma", "Stage IB2 Cervical Cancer AJCC v6 and v7", "Stage II Cervical Cancer AJCC v7", "Stage II Vaginal Cancer AJCC v6 and v7", "Stage IIA Cervical Cancer AJCC v7", "Stage IIB Cervical Cancer AJCC v6 and v7", "Stage III Vaginal Cancer AJCC v6 and v7", "Stage IIIB Cervical Cancer AJCC v6 and v7", "Stage IV Vaginal Cancer AJCC v6 and v7", "Stage IVA Cervical Cancer AJCC v6 and v7", "Stage IVA Vaginal Cancer AJCC v6 and v7", "Unresectable Vaginal Carcinoma", "Vaginal Adenocarcinoma", "Vaginal Adenosquamous Carcinoma", "Vaginal Carcinoma", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified" ], "interventions": [ { "name": "Brachytherapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Triapine", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 450, "start_date": "2016-05-10", "completion_date": "2027-07-14", "has_results": true, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-25T19:26:24.635Z", "location_count": 377, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 253 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02466971" }, { "nct_id": "NCT04465487", "title": "Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "REGN6569", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2020-10-05", "completion_date": "2025-02-07", "has_results": false, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-10-25T19:26:24.635Z", "location_count": 4, "location_summary": "Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04465487" }, { "nct_id": "NCT05359692", "title": "INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Head and Neck Squamous Cell Carcinoma", "Advanced Malignancies", "Recurrent Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "INCAGN01876", "type": "BIOLOGICAL" }, { "name": "retifanlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 0, "start_date": "2023-03-01", "completion_date": "2025-01-11", "has_results": false, "last_update_posted_date": "2023-09-15", "last_synced_at": "2026-10-25T19:26:24.635Z", "location_count": 17, "location_summary": "Birmingham, Alabama • La Jolla, California • Palo Alto, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05359692" }, { "nct_id": "NCT04799054", "title": "A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Locally Advanced Solid Tumor", "Metastatic Solid Tumor", "Head and Neck Squamous Cell Carcinoma HNSCC", "HPV-associated Cancers", "Neoadjuvant Melanoma", "Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)" ], "interventions": [ { "name": "TransCon TLR7/8 Agonist", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascendis Pharma Oncology Division A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 188, "start_date": "2021-03-18", "completion_date": "2025-12-02", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-25T19:26:24.635Z", "location_count": 17, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04799054" } ] }